Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 86 publications
Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
Concurrent BCR::ABL1 and SET::NUP214 fusions in blast-phase chronic myeloid leukemia.
Journal: Cancer genetics
Published: July 20, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
Journal: British journal of haematology
Published: July 02, 2026
Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.
Journal: European journal of haematology
Published: May 27, 2026
Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Journal: American journal of hematology
Published: March 09, 2026
Menin inhibitors as a treatment for acute leukemia: from bench to the clinic.
Journal: Blood neoplasia
Published: January 28, 2026
Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Journal: Advances in therapy
Published: December 17, 2025
Balancing Activation and Repression: CoREST-p300 Antagonism Controls Retinoic Acid-Driven Differentiation in AML.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings.
Journal: Leukemia & lymphoma
Published: August 25, 2025
Last Updated: 09/26/2026